Buscar
09/06/2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Perl, AE, Larson, RA, Podoltsev, NA, Strickland, S, Wang, ES, Atallah, E, Schiller, GJ, Martinelli, G, Neubauer, A, Sierra, J, Montesinos, P, Recher, C, Yoon, SS, Hosono, N, Onozawa, M, Chiba, S, Kim, HJ, Hasabou, N, Lu, QY, Tiu, R, Levis, MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. BLOOD. 2022; 139(23)DOI:10.1182/blood.2021011583. PMID:35081255. IF:20.300(Q1/1D).
03/06/2022
Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups
Kaivola, K, Shah, Z, Chia, R, Scholz, SW, Alcolea, D., Clarimón, J., Fortea, J., Lleó, A., Int LBD Genomics Consortium. Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. BRAIN. 2022; 145(5)DOI:10.1093/brain/awab402. PMID:35381062. IF:14.500(Q1/1D).
03/06/2022
Challenges for asthma units in response to COVID-19: a qualitative group dynamics analysis
Rivera, CM, Crespo-Lessman, A, Arismendi, E, Munoz-Esquerre, M, Aguilar, X, Ausin, P, Bobolea, I, Duch, GD, Teixido, RP, Talaverano, GS, Sabardia, AS, Gall, XM. Challenges for asthma units in response to COVID-19: a qualitative group dynamics analysis. JOURNAL OF ASTHMA. 2022; 59(6)DOI:10.1080/02770903.2021.1917605. PMID:33882776. IF:1.900(Q4/8D).
02/06/2022
A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
Kulisevsky, J, Martinez-Horta, S, Campolongo, A, Pascual-Sedano, B, Marin-Lahoz, J, Bejr-kasem, H, Aracil-Bolanos, I, Horta-Barba, A, Puig-Davi, A, Pagonabarraga, J. A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease. Frontiers in Neurology. 2022; 13DOI:10.3389/fneur.2022.866502. PMID:35720066. IF:3.400(Q2/5D).